Ambit to Present at JMP Securities Healthcare Conference
SAN DIEGO, July 3, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that Michael Martino, president and CEO, is scheduled to present a company overview at the 8th Annual JMP Securities Healthcare Conference. Mr. Martino's presentation is scheduled to take place at 9:30 a.m. EDT on Wednesday, July 10, at the St. Regis New York.
A live webcast of the presentation will be accessible in the investors section of the company's website, www.ambitbio.com, with an archived recording available for 90 days.
About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Because such statements are subject to risks and uncertainties, actual results and performance may differ materially from those expressed or implied by such forward-looking statements. Risks that could affect Ambit are described in Ambit's SEC filings.
Robert Flamm, Ph.D. (Investor)
SOURCE Ambit Biosciences Corporation
More by this Source
Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
Aug 13, 2013, 16:02 ET
Data from Phase 2 ACE Study of Ambit's Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) Presented at 18th Congress of the European Hematology Association
Jun 26, 2013, 08:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.